Latest From Celltrion Inc.
Celltrion head of clinical development Sang Joon Lee has set out the promise of ‘biobetters’ – biosimilars that improve upon the original reference product – at the FT Global Pharmaceutical and Biotechnology Conference 2019. However, obstacles remain, including the lack of a tailored regulatory pathway.
Truxima will launch in the US on 11 November for oncology indications at a 10% discount to the list price of Roche’s innovator Rituxan. The launch marks Teva's first biosimilar launch in the US.
Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.
Amid declining sales of drugs covered by reference prices in Finland, local leader Orion says it has been able to slightly strengthen its market position.
- Large Molecule
- Contract Research, Toxicology Testing-CRO
- Generic Drugs
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- Musculoskeletal & Connective Tissue Disorders
- Respiratory, Pulmonary
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Celltrion Inc.
- Senior Management
- Hyoung-Ki Kim, Co-CEO
- Contact Info
Phone: (82) 32 850 5000
Incheon City, 406-840
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.